Haverford Financial Services Inc. decreased its stake in Becton Dickinson and Co (NYSE:BDX) by 0.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,841 shares of the medical instruments supplier’s stock after selling 99 shares during the period. Becton Dickinson and accounts for 2.3% of Haverford Financial Services Inc.’s portfolio, making the stock its 20th largest position. Haverford Financial Services Inc.’s holdings in Becton Dickinson and were worth $6,790,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in BDX. Daiwa Securities Group Inc. raised its stake in Becton Dickinson and by 91.2% during the 3rd quarter. Daiwa Securities Group Inc. now owns 21,062 shares of the medical instruments supplier’s stock valued at $5,328,000 after acquiring an additional 10,044 shares in the last quarter. Donaldson Capital Management LLC raised its stake in Becton Dickinson and by 21.0% during the 3rd quarter. Donaldson Capital Management LLC now owns 1,079 shares of the medical instruments supplier’s stock valued at $273,000 after acquiring an additional 187 shares in the last quarter. James Hambro & Partners bought a new stake in Becton Dickinson and during the 3rd quarter valued at $33,450,000. Keybank National Association OH raised its stake in Becton Dickinson and by 2.3% during the 3rd quarter. Keybank National Association OH now owns 70,137 shares of the medical instruments supplier’s stock valued at $17,742,000 after acquiring an additional 1,598 shares in the last quarter. Finally, Hemenway Trust Co LLC raised its stake in Becton Dickinson and by 58.4% during the 3rd quarter. Hemenway Trust Co LLC now owns 42,313 shares of the medical instruments supplier’s stock valued at $10,703,000 after acquiring an additional 15,596 shares in the last quarter. 84.29% of the stock is currently owned by institutional investors and hedge funds.
In other news, CEO Vincent A. Forlenza sold 11,532 shares of Becton Dickinson and stock in a transaction on Friday, September 6th. The stock was sold at an average price of $260.38, for a total transaction of $3,002,702.16. Following the transaction, the chief executive officer now owns 218,671 shares in the company, valued at $56,937,554.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Alexandre Conroy sold 9,829 shares of Becton Dickinson and stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $255.06, for a total value of $2,506,984.74. Following the transaction, the executive vice president now owns 16,535 shares in the company, valued at approximately $4,217,417.10. The disclosure for this sale can be found here. Insiders have sold 32,174 shares of company stock worth $8,354,013 in the last quarter. 0.12% of the stock is currently owned by corporate insiders.
Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.30 by $0.01. The business had revenue of $4.58 billion for the quarter, compared to analysts’ expectations of $4.57 billion. Becton Dickinson and had a return on equity of 15.51% and a net margin of 6.84%. The company’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.93 EPS. On average, research analysts expect that Becton Dickinson and Co will post 12.58 EPS for the current year.
BDX has been the topic of several recent analyst reports. Piper Jaffray Companies cut their target price on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Wells Fargo & Co dropped their price objective on Becton Dickinson and from $290.00 to $285.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, Morgan Stanley boosted their price objective on Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 16th. Five equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Becton Dickinson and presently has a consensus rating of “Buy” and an average price target of $266.09.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: How does a reverse stock split work?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.